Mania

Feb 19, 2020

Global Trichotillomania (TTM) Pipeline Overview 2020: Therapeutic Assessment, Product Profiles, Unmet Needs, Key Companies

May 28, 2019

Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression

Jan 17, 2019

Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

Dec 05, 2018

Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting

Nov 27, 2018

What It Means to be Bipolar; Understanding symptoms and treatments

Nov 16, 2018

Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

Oct 11, 2018

The Difference a Diagnosis Makes: How Understanding Fear of Harm Syndrome May Help Save Your Child

Sep 05, 2018

Global Bipolar Disorder Disease Market 2018-2024 - Otsuka initiates Phase III Development of Rexulti for Bipolar Mania Without Proof-of-Concept Trial

Aug 09, 2018

HabitAware Receives $300,000 NIH Research Grant to Develop Innovative Awareness Bracelet as a Treatment for Trichotillomania (Hair Pulling Disorder)

Nov 20, 2017

Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders

Nov 14, 2017

Otsuka And Proteus® Announce The First U.S. FDA Approval Of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)